Voluntary Disclosure Announcement on Approval of Phase II Clinical Trial for New Indication of Immune Reconstitution Insufficient of Aikening

About this update from Frontier Biotechnologies Inc. Class A

Voluntary Disclosure Announcement on Approval Notice of Phase II Clinical Trial for New Indication of Incomplete Immune Reconstitution of AikeningThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Frontier Biotechnologies Inc. Class A